公开(公告)号：EP3885360A1

公开(公告)日：2021-09-29

申请号：EP19887601.3

申请日：2019-11-22

申请人： Celltrion, Inc.

发明人： KIM, Sung Hyun ,  AN, Hyun Chul ,  LEE, Sang Joon ,  LEE, Se Won ,  JEON, Da Bee

IPC分类号： C07K16/10 ,  A61P31/16 ,  A61K39/00

摘要： The present invention pertains to a dosing regimen for treating influenza virus diseases, and more specifically, to a method for treating influenza virus-related diseases through the administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. The treatment method according to the present invention enables influenza A virus-related diseases to be treated through the intravenous administration of a mixed composition of monoclonal antibodies having a neutralizing activity against the influenza A virus. In addition, the treatment method according to the present invention can satisfy unmet medical needs for biological therapeutic agents for influenza virus-related diseases.

公开(公告)号：EP3858816A1

公开(公告)日：2021-08-04

申请号：EP19864449.4

申请日：2019-09-20

申请人： Celltrion, Inc.

发明人： DESI REDDY, Srinivas Reddy ,  MATHAD, Vijayavitthal Thippannachar ,  RANE, Dnyandev Ragho ,  PATIL, Vikas Shivaji

IPC分类号： C07D233/06 ,  A61K31/4164 ,  A61P9/06

摘要： The present invention relates to a crystal form of (-)-Cibenzoline succinate. In addition, the present invention relates to a method for preparing (-)-cibenzoline succinate having a chiral purity of 99.9% or higher. Additionally, the present invention provides a method for preparing (-)-cibenzoline succinate and a crystal form thereof.

公开(公告)号：EP3533441A2

公开(公告)日：2019-09-04

申请号：EP17863573.6

申请日：2017-10-26

申请人： Celltrion Inc.

发明人： LEE, Joon Won ,  HAN, Won Yong ,  KIM, Su Jung ,  OH, Jun Seok ,  KIM, So Young ,  KIM, Kwang Woo ,  SHIN, Yeon Kyeong

IPC分类号： A61K9/08 ,  A61K47/12 ,  A61K9/00 ,  A61K38/16

摘要： Disclosed is a stable pharmaceutical formulation, comprising a fusion protein in which the extracellular ligand-binding domain of a human p75 tumor necrosis factor receptor is fused to the Fc domain of human IgG and a succinate buffering agent, without comprising a stabilizer. The stable pharmaceutical formulation enables the long-term storage of the TNFR-Fc fusion protein formulation and can exhibit superior storage stability without the need for demanding storage conditions, and is a simple formulation because no stabilizer is comprised therein and is thus more economical than other stabilizer-comprising formulations.

公开(公告)号：EP3228323A1

公开(公告)日：2017-10-11

申请号：EP15866215.5

申请日：2015-12-05

申请人： Celltrion Inc.

发明人： CHANG, Shin Jae ,  LEE, Soo Young ,  LIM, Byung Pil ,  KIM, Pan Kyeom ,  PARK, Sang Tae ,  AHN, Jung Sun ,  PARK, Eun Bee ,  KEUM, Sun Ju ,  SONG, Man Ki ,  CHOI, Jung Ah

IPC分类号： A61K39/39 ,  A61K39/145 ,  A61P31/12 ,  A61K39/395 ,  C12N5/0781 ,  C12N5/0783 ,  C07K16/00

CPC分类号： A61K39/39 ,  A61K39/145 ,  A61K39/395 ,  A61K39/42 ,  A61K2039/505 ,  A61K2039/55516 ,  A61K2039/575 ,  C07K16/00 ,  C07K16/1018 ,  C07K2317/565 ,  C12N7/00 ,  C12N2760/16134 ,  C12N2760/16171

摘要： This invention relates to an adjuvant composition containing at least one binding molecule for neutralizing influenza virus and a vaccine composition containing the same. The composition containing at least one binding molecule for neutralizing influenza virus is capable of increasing the effects of a vaccine, and can thus be used as an adjuvant, which increases an immune response upon vaccine administration, and is very useful in the prevention of diseases caused by viruses.

摘要翻译： 本发明涉及含有至少一种用于中和流感病毒的结合分子的佐剂组合物和含有该组合物的疫苗组合物。 含有至少一种用于中和流感病毒的结合分子的组合物能够增加疫苗的效果，并因此可以用作佐剂，其在疫苗施用后增加免疫应答，并且对于预防所引起的疾病非常有用 由病毒。

公开(公告)号：EP2762491B1

公开(公告)日：2017-07-05

申请号：EP12835569.0

申请日：2012-09-27

申请人： Celltrion, Inc.

发明人： CHANG, Shin Jae ,  KWON, Ki Sung ,  YI, Kye Sook ,  LEE, Hyun Joo ,  JEON, Jae Won ,  JUN, Hwang Keun ,  CHANG, Min Seok

IPC分类号： C07K16/06 ,  C12N15/13 ,  A61K39/42 ,  C07K16/10 ,  G01N33/569 ,  A61K39/00

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/76 ,  G01N33/56983 ,  G01N33/577 ,  G01N2333/11 ,  G01N2500/00

摘要： The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.

摘要翻译： 本发明涉及来源于人B细胞的具有甲型流感病毒中和活​​性的结合分子，根据本发明，具有甲型流感病毒中和活​​性的结合分子是源自 B细胞，其选自感染甲型流感病毒的患者的血液，并且具有对甲型流感病毒的中和活性，因此可用于预防和治疗源自甲型流感病毒的疾病，并且可用于诊断 通过使用根据本发明的结合分子的甲型流感病毒。

公开(公告)号：EP2418282B1

公开(公告)日：2017-05-10

申请号：EP10758995.4

申请日：2010-03-30

申请人： Celltrion, Inc.

发明人： CHO, MyungSam ,  CHANG, Min Seok ,  KIM, Jong-Mook ,  LEE, HyunJoo ,  SONG, Yoo Cheol ,  KIM, ManSu

IPC分类号： C12N15/65 ,  C12N15/64 ,  C12N15/52

CPC分类号： C12N15/65 ,  C12N15/1086 ,  C12N15/69 ,  C12N15/85 ,  C12N2800/24 ,  C12N2830/46 ,  C12N2830/50 ,  C12P21/02

公开(公告)号：EP2860190A3

公开(公告)日：2015-07-15

申请号：EP14181741.1

申请日：2011-03-07

申请人： Celltrion, Inc.

发明人： Shin Jae, Chang ,  Jong Mook, Kim ,  Kye Sook, Yi ,  Hyun Joo, Lee

IPC分类号： C07K16/10 ,  A61K39/145

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

摘要： The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

公开(公告)号：EP2889287A1

公开(公告)日：2015-07-01

申请号：EP13839929.0

申请日：2013-09-16

申请人： Celltrion, Inc.

发明人： PARK, Young Jun ,  JEONG, Jin-kyo ,  CHOI, Young Mi ,  LEE, Min Seob ,  CHOI, Joon hun ,  CHO, Eun Joo ,  SONG, Hyunnam ,  PARK, Sung Jun ,  LEE, Jong-hyoup ,  HONG, Seung Suh

IPC分类号： C07D207/12 ,  A61K31/40 ,  A61P35/00

CPC分类号： C07K7/06 ,  A61K31/40 ,  A61K31/421 ,  A61K31/426 ,  A61K38/00 ,  C07D207/12 ,  C07D401/12 ,  C07D409/12 ,  C07K5/0205 ,  C07K5/06052

摘要： The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.

摘要翻译： 本发明提供具有优异的抗癌活性的多拉司他汀-10衍生物，其制备方法和含有该活性成分的抗癌药物组合物。

公开(公告)号：EP2762491A4

公开(公告)日：2015-05-20

申请号：EP12835569

申请日：2012-09-27

申请人： CELLTRION INC

发明人： CHANG SHIN JAE ,  KWON KI SUNG ,  YI KYE SOOK ,  LEE HYUN JOO ,  JEON JAE WON ,  JUN HWANG KEUN ,  CHANG MIN SEOK

IPC分类号： C07K16/06 ,  A61K39/00 ,  A61K39/42 ,  C07K16/10 ,  C12N15/13 ,  G01N33/569

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/76 ,  G01N33/56983 ,  G01N33/577 ,  G01N2333/11 ,  G01N2500/00

摘要： The present invention relates to a binding molecule having influenza A virus-neutralizing activity derived from a human B cell, and the binding molecule having the influenza A virus-neutralizing activity, according to the present invention, is a binding molecule that is derived from a B cell that is selected from the blood of a patient infected with an influenza A virus, and has neutralizing activity against influenza A viruses, and thus is useful in preventing and treating disease derived from the influenza A virus, and can be useful in diagnosing the influenza A virus by using the binding molecule according to the present invention.

摘要翻译： 本发明涉及根据本发明的具有源自人B细胞的甲型流感病毒中和活​​性的结合分子和具有甲型流感病毒中和活​​性的结合分子，其是衍生自 B细胞，其选自感染甲型流感病毒的患者的血液，并且具有针对甲型流感病毒的中和活性，因此可用于预防和治疗来源于甲型流感病毒的疾病，并且可用于诊断 通过使用根据本发明的结合分子的甲型流感病毒。

公开(公告)号：EP2545074A2

公开(公告)日：2013-01-16

申请号：EP11753571.6

申请日：2011-03-07

申请人： Celltrion, Inc.

发明人： SHIN JAE, Chang ,  JONG MOOK, Kim ,  KYE SOOK, Yi ,  HYUN JOO, Lee

IPC分类号： C07K16/10 ,  C12N15/44 ,  C12N15/63 ,  G01N33/53

CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

摘要： The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.